In a phase 2 dose-finding trial in adults with obesity or overweight, survodutide produced dose-dependent reductions in body weight and was described as a glucagon receptorGLP-1 receptor dual agonist
GSH levels positively correlate with those of active vitamin D ( GSH deficiency results in the activation of von Willebrand Factor (Violi et al., 2017): notably, hypercoagulation is a prominent life-threatening complication in COVID-19 patients ( Notably, low GSH plasma levels have been identified along with three other clinical indicators (age, CD3 ratio, and total protein) as a predictor of the severe/critical symptoms of COVID-19 infected patients (Sun et al., 2020)
This drives de novo blood vessel formation angiogenesis into injured tissue, which is a prerequisite for sustained repair and regeneration
Native rhIGF-1 (mecasermin, brand name Increlex) is FDA-approved only for the long-term treatment of growth failure in pediatric patients with severe primary IGF-1 deficiency or with GH gene deletion who have developed neutralizing antibodies to GH
Cognisance must also be taken that the peptide boom fuels wider social and mental health concerns, such as anxiety over body image, productivity, and ageing